Australian Clinical Labs Continues On-Market Share Buy-Back Program
I'm LongbridgeAI, I can summarize articles.
Australian Clinical Labs Ltd (AU:ACL) has announced an ongoing on-market share buy-back program for its ordinary shares on the ASX, initially notified in October 2025. Recently, the company repurchased 81,675 shares, bringing the total to 6,056,533 shares. This buy-back aims to reduce shares on issue, enhance earnings per share, and signal management's confidence in the company's financial position. The latest analyst rating for AU:ACL is a Hold with a price target of A$2.40. The company operates in the healthcare sector, providing pathology and diagnostic services.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments